ClinicalTrials.gg
RecruitingNCT07183891Updated Sep 19, 2025

Performance of Large Language Models for Structured Recognition and Refractive Prediction

An observational study in Cataract, sponsored by Jin Yang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Jin Yang · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.

Planned enrollment
44th of 73
100 · median 120
Started
2025
with 14 others
Observational
73 of 184
19 open now
Primary completion
2030-12
later than 44 of 48 live
Registered
162nd of 184
by date
Lead sponsor
6 of 184
Jin Yang

Among the 184 studies in Cataract with a site in China, this one is the 44th largest by planned enrollment of the 73 observational ones that give a count, is one of 15 that started in 2025, is one of 73 observational ones, reaches primary completion later than 44 of the 48 other live ones, and was the 162nd registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Cataract with a site in China, or all of them as a file.
02

Study summary

We conducted a single-center, retrospective observational study to evaluate large language models (ChatGPT 4o, GPT-5, DeepSeek) for automated interpretation of de-identified IOLMaster 700 reports provided as raster images. Models produced structured biometric extraction, toric IOL recommendation, and refractive predictions (sphere, cylinder, axis). Primary outcomes included parameter-level agreement and refractive error metrics; secondary outcomes included decision-support performance for toric IOL selection and agreement on ordered T-codes. No clinical intervention was performed.

Read the detailed description

This study compares three large language models accessed in their native configurations, without fine-tuning or external tools. For each examination, the original IOLMaster 700 report image was supplied without manual annotation or pre-processing. A standardized instruction required: (i) structured extraction of AL, ACD, LT, WTW, K1/K2 and axes, ΔK, TK1/TK2 and axes, and ΔTK; (ii) binary toric candidacy and T-code according to institutional ALCON mapping; and (iii) refractive recommendations (sphere, cylinder, implantation axis). Each model generated three independent outputs per case. De-identification and IRB oversight (waiver of consent) were implemented according to institutional policy. The unit of enrollment is participants (n=54), with outcomes analyzed per eye (162 eyes) and per model generation where applicable.

03

Conditions studied

  • Cataract

Keywords

  • cataract
  • toric IOL
  • astigmatism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

cataract patients who had undergone phacoemulsification and implantation of an AcrySof IQ Toric monofocal intraocular lens

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-postoperative corrected distance visual acuity (CDVA) of 0.10 logMAR or better -an absolute IOL rotational stability of less than 10∘ at the 1-month follow-up examination

Exclusion criteria

Exclusion Criteria:

  • incomplete biometric data on the examination report;
  • a history of previous ocular surgery or ocular trauma
  • the occurrence of intraoperative complications, such as an anterior capsular tear or posterior capsular rupture
  • the development of significant postoperative complications, including but not limited to severe intraocular infection or inadequate pupillary dilation.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Refractive prediction error for sphere

    Mean absolute error (MAE, diopters) of model-predicted sphere versus clinical reference

    Time frame: At index examination

  2. Cohen's kappa with 95% CIs between model

    Cohen's kappa with 95% CIs between model outputs and clinician-validated reference for per-parameter

    Time frame: At index examination (single time point)

Secondary outcomes

  1. Cylinder prediction error

    Mean absolute error (MAE, diopters) of model-predicted Cylinder

    Time frame: At index examination

  2. Axis prediction error

    Mean absolute error (MAE, diopters) of model-predicted Axis

    Time frame: At index examination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2030, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2025
First posted
Sep 19, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07183891
Lead sponsor
Jin Yang
Responsible party
Jin Yang (Chief Physician, Eye & ENT Hospital of Fudan University) — Sponsor-investigator
First posted
Sep 19, 2025
Start date
Aug 1, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 19, 2025

Study contacts

Xuanqiao Lin
Contact
1532483480@qq.com
+8615088920668

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion